Literature DB >> 12584693

The antitumor potential of bisphosphonates.

Philippe Clézardin1.   

Abstract

Bisphosphonates are primarily known for their ability to inhibit osteoclast-mediated bone resorption and to slow the release of calcium and other bone minerals into the blood stream. However, recent preclinical research has shown that bisphosphonates also exhibit potent antitumor activity. Bisphosphonates reduce proliferation and induce apoptosis of tumor cell lines, and they inhibit tumor cell adhesion and invasion of the extracellular matrix in vitro. In addition, bisphosphonates have been shown to reduce skeletal tumor burden in a variety of animal models. This may reflect either direct antitumor effects or indirect effects via osteoclast inhibition and alteration of the bone microenvironment. The complex mechanisms by which bisphosphonates inhibit bone resorption and interfere with tumor growth and metastasis to bone are beginning to be understood. Research is ongoing to fully elucidate these biochemical mechanisms, and well-designed clinical trials are planned to investigate the antitumor potential of modern nitrogen-containing bisphosphonates in the clinical setting. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12584693     DOI: 10.1053/sonc.2002.37420

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  10 in total

1.  A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Authors:  Monica M Reinholz; Shawn P Zinnen; Amylou C Dueck; David Dingli; Gregory G Reinholz; Leslie A Jonart; Kathleen A Kitzmann; Amy K Bruzek; Vivian Negron; Abdalla K Abdalla; Bonnie K Arendt; Anthony J Croatt; Luis Sanchez-Perez; David P Sebesta; Harri Lönnberg; Toshiyuki Yoneda; Karl A Nath; Diane F Jelinek; Stephen J Russell; James N Ingle; Thomas C Spelsberg; Henry B F Hal Dixon; Alexander Karpeisky; Wilma L Lingle
Journal:  Bone       Date:  2010-03-15       Impact factor: 4.398

2.  Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline.

Authors:  Kyriaki Mystakidou; Emmanuela Katsouda; Efi Parpa; Alexis Kelekis; Antonis Galanos; Lambros Vlahos
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors:  Amal A El-Mabhouh; John R Mercer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

4.  Bone marrow angiogenesis and progression in multiple myeloma.

Authors:  Roberto Ria; Antonia Reale; Annunziata De Luisi; Arianna Ferrucci; Michele Moschetta; Angelo Vacca
Journal:  Am J Blood Res       Date:  2011-06-08

5.  Use of bisphosphonates and reduced risk of colorectal cancer.

Authors:  Gad Rennert; Mila Pinchev; Hedy S Rennert; Stephen B Gruber
Journal:  J Clin Oncol       Date:  2011-02-14       Impact factor: 44.544

6.  Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis.

Authors:  Stefanos Bonovas; Georgios Nikolopoulos; Pantelis Bagos
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

Review 7.  Therapy strategies for multiple myeloma: current status.

Authors:  Heinz Gisslinger; Mathias Kees
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

8.  Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma.

Authors:  Agustin Avilés; María J Nambo; Natividad Neri; Claudia Castañeda; Sergio Cleto; Judith Huerta-Guzmán
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

9.  Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.

Authors:  Irene Dell'Anno; Sarah A Martin; Marcella Barbarino; Alessandra Melani; Roberto Silvestri; Maria Bottaro; Elisa Paolicchi; Alda Corrado; Monica Cipollini; Ombretta Melaiu; Antonio Giordano; Luca Luzzi; Federica Gemignani; Stefano Landi
Journal:  Invest New Drugs       Date:  2020-12-09       Impact factor: 3.850

10.  Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells.

Authors:  A-M Forsea; C Müller; C Riebeling; C E Orfanos; C C Geilen
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.